Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

NCT07346807 | Not Yet Recruiting Phase 2

• 1 other identifier: B2025-792R
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate the feasibility and preliminary efficacy of lingual nerve disruption combined with neoadjuvant chemoimmunotherapy in patients with locally advanced tongue squamous cell carcinoma. The study aims to learn whether surgical disruption of the lingual nerve can enhance the effectiveness of neoadjuvant chemoimmunotherapy before definitive surgery in adults with locally advanced (cT3/T4) tongue cancer. The main questions it aims to answer are: Can lingual nerve disruption combined with neoadjuvant chemoimmunotherapy improve tumor response prior to surgery? Is this combined treatment approach safe and feasible for patients with locally advanced tongue cancer? This is a single-arm, phase II clinical trial. Participants will: Undergo tumor biopsy with simultaneous surgical disruption of the affected-side lingual nerve. Receive neoadjuvant chemoimmunotherapy consisting of tislelizumab, cisplatin, and nab-paclitaxel for two treatment cycles. Undergo definitive surgical resection of the primary tumor and neck dissection. Attend scheduled follow-up visits for safety assessments, imaging evaluations, and collection of blood samples for immune monitoring.

Conditions

Tongue Squamous Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Major Pathologic Response (MPR) Rate

  From baseline (day1, before biopsy and lingual nerve disruption) to surgery (3 weeks after completion of 2 cycles of neoadjuvant therapy, which starts 1 week after the biopsy. Each cycle of neoadjuvant therapy is 21 days/3 weeks)

Secondary Outcomes (1)

• Preoperative Pain Score Improvement Rate

  From baseline (day1, before biopsy and lingual nerve disruption) to surgery (3 weeks after completion of 2 cycles of neoadjuvant therapy, which starts 1 week after the biopsy. Each cycle of neoadjuvant therapy is 21 days/3 weeks)

Other Outcomes (1)

• Dynamic Changes of Immune Cells

  At 5 specific time points during the study: Baseline (day1) Before second cycle of neoadjuvant therapy (day28 / 4 weeks) After second cycle of neoadjuvant therapy before surgery (day49 / 7weeks) 4 weeks after surgery(day77) 3 months after surgery(day139)

Study Arms (1)

Lingual Nerve Disruption + Neoadjuvant Chemoimmunotherapy

EXPERIMENTAL

Procedure: Lingual Nerve Disruption; Drug: Tislelizumab; Drug: Albumin-bound Paclitaxel; Procedure: Cisplatin; Procedure: Peripheral Blood Collection for Immune Monitoring; Other: Pain and Quality of Life Assessment

Interventions

Lingual Nerve Disruption PROCEDURE

Surgical transection of 1 cm of the lingual nerve via intraoral approach under local anesthesia at the time of biopsy. This procedure induces ipsilateral tongue tip numbness to enhance subsequent chemoimmunotherapy efficacy.

Lingual Nerve Disruption + Neoadjuvant Chemoimmunotherapy

Tislelizumab DRUG

Anti-PD-1 monoclonal antibody administered intravenously at 200 mg on day 1 of each 3-week cycle.

Lingual Nerve Disruption + Neoadjuvant Chemoimmunotherapy

Albumin-bound Paclitaxel DRUG

Chemotherapy agent administered intravenously at 260 mg/m² on day 2 of each 3-week cycle.

Lingual Nerve Disruption + Neoadjuvant Chemoimmunotherapy

Cisplatin PROCEDURE

Chemotherapy agent administered intravenously at 75 mg/m² on day 2-3 of each 3-week cycle.

Lingual Nerve Disruption + Neoadjuvant Chemoimmunotherapy

Peripheral Blood Collection for Immune Monitoring PROCEDURE

Peripheral blood (10 mL) collected in the morning under fasting conditions at baseline, before each cycle of neoadjuvant therapy, and during follow-up visits. Plasma and peripheral blood mononuclear cells are prepared within 2 hours and stored at -80°C for immune cell dynamic analysis.

Lingual Nerve Disruption + Neoadjuvant Chemoimmunotherapy

Pain and Quality of Life Assessment OTHER

McGill Pain Questionnaire and quality-of-life surveys administered before each cycle of neoadjuvant therapy to assess treatment impact on pain relief and functional outcomes.

Lingual Nerve Disruption + Neoadjuvant Chemoimmunotherapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18-75 years, male or female.
• Histologically or cytologically confirmed primary tongue squamous cell carcinoma (cT3 or cT4).
• Patients scheduled to receive 2 cycles of preoperative neoadjuvant chemoimmunotherapy with tirelizumab, cisplatin, and albumin-bound paclitaxel.
• Patients planned to undergo surgical resection of tongue cancer following neoadjuvant therapy.
• Voluntary participation with signed informed consent, good compliance, and willingness to follow study procedures.

You may not qualify if:

• Known distant metastases of the tumor.
• History of tongue squamous cell carcinoma or other malignant tumors of the tongue within the past 5 years.
• Active infection requiring systemic therapy; non-infectious pneumonia or interstitial lung disease requiring steroid therapy, or current pneumonia/interstitial lung disease; known hepatitis B infection (HBsAg positive) or active hepatitis C infection (detectable HCV RNA); known HIV infection.
• Previous allogeneic tissue or organ transplantation.
• Unresolved ≥Grade 2 (CTCAE v5.0) toxicities from prior anticancer treatments, except alopecia.
• Significant cardiovascular abnormalities (e.g., myocardial infarction, superior vena cava syndrome, NYHA class ≥II heart disease within 3 months prior to enrollment).
• Active serious clinical infections (\>Grade 2 NCI-CTCAE v5.0).
• Uncontrolled hypertension (treated systolic BP \>150 mmHg and/or diastolic BP \>90 mmHg) or clinically significant cardiovascular disease, including recent cerebrovascular accident or myocardial infarction (≤6 months), unstable angina, NYHA class ≥II congestive heart failure, or severe arrhythmia not controlled by medication that could affect study treatment.
• Laboratory abnormalities:
• Hematology: WBC \<3,000/mm³, Hb \<8 g/dL, platelets \<80,000/mm³ Liver function: ALT/AST \>3× upper limit of normal, bilirubin \>1.5× ULN Renal function: serum creatinine \>1.5× ULN, renal failure requiring dialysis Diabetes: poorly controlled (FBG \>10 mmol/L) Proteinuria: urine protein ≥++ and 24-hour urine protein \>1.0 g
• Pregnant women; breastfeeding women must discontinue breastfeeding to participate.
• History of substance abuse or psychiatric disorders that would interfere with study participation.
• Participation in another clinical trial within 30 days prior to enrollment.

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead

Study Sites (1)

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location

MeSH Terms

Interventions

tislelizumab; Albumin-Bound Paclitaxel; Cisplatin; Monitoring, Immunologic

Intervention Hierarchy (Ancestors)

Paclitaxel; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Albumins; Proteins; Amino Acids, Peptides, and Proteins; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Immunologic Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Monitoring, Physiologic; Investigative Techniques; Immunologic Techniques

Central Study Contacts

Tong Ji, PhD

CONTACT

86-13651658767; ji.tong@zs-hospital.sh.cn

Yu Zhang, PhD

CONTACT

86-13818927554; zhang.yu4@zs-hospital.sh.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 24, 2025
• First Posted: January 16, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): October 31, 2026
• Study Completion (Estimated): October 31, 2026
• Last Updated: January 16, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)